UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 136

Sortiert nach

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis

Annals of oncology, 2012-10, Vol.23 (10), p.2656-2662

2012

Volltextzugriff (PDF)

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

European journal of cancer (1990), 2017-07, Vol.79, p.50-60

2017

Volltextzugriff (PDF)

Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial

Annals of oncology, 2018-12, Vol.29 (12), p.2393-2395

2018

Volltextzugriff (PDF)

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)

European journal of cancer (1990), 2017-10, Vol.84, p.262-269

2017

Volltextzugriff (PDF)

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

ESMO open, 2023-10, Vol.8 (5), p.101623-101623, Article 101623

2023

Volltextzugriff (PDF)

The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)

Annals of oncology, 2015-06, Vol.26 (6), p.1244-1248

2015

Volltextzugriff (PDF)

“The German- Registry” of incidental gallbladder cancer and the GAIN - phase III trial: Transformation from a registry to treatment platform due to a trial in trial concept

Annals of oncology, 2018-10, Vol.29, p.viii263-viii263

2018

Volltextzugriff (PDF)

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer

British journal of cancer, 2013-02, Vol.108 (3), p.519-526

2013

Volltextzugriff (PDF)

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma

Journal of cellular and molecular medicine, 2008-12, Vol.12 (6a), p.2457-2466

2008

Volltextzugriff (PDF)

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)

Annals of oncology, 2018-10, Vol.29, p.viii245-viii246

2018

Volltextzugriff (PDF)

Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Annals of oncology, 2009-03, Vol.20 (3), p.481-485

2009

Volltextzugriff (PDF)

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas

Annals of oncology, 2011-08, Vol.22 (8), p.1839-1844

2011

Volltextzugriff (PDF)

Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)

Annals of oncology, 2018-10, Vol.29, p.viii265-viii266

2018

Volltextzugriff (PDF)

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Annals of oncology, 2019-09, Vol.30 (9), p.1487-1495

2019

Volltextzugriff (PDF)

Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer

Annals of oncology, 2018-10, Vol.29, p.viii205-viii206

2018

Volltextzugriff (PDF)

Quality of life (QoL) in patients with metastatic pancreatic cancer receiving first-line Nab-paclitaxel/gemcitabine chemotherapy: Results of the large QoL study AIO-QoliXane/PARAGON

Annals of oncology, 2018-10, Vol.29, p.viii252-viii252

2018

Volltextzugriff (PDF)

Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)

Annals of oncology, 2018-10, Vol.29, p.viii39-viii39

2018

Volltextzugriff (PDF)

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Annals of oncology, 2020-02, Vol.31 (2), p.228-235

2020

Volltextzugriff (PDF)

Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306)

Annals of oncology, 2014-06, Vol.25, p.ii117-ii117

2014

Volltextzugriff (PDF)

Vom „Stiefkind“ zum Paradebeispiel

Der Onkologe, 2013-05, Vol.19 (5), p.350-351

2013

Volltextzugriff (PDF)

Behandlungsalgorithmen für Adenokarzinome des Magens oder ösophagogastralen Übergangs

Der Onkologe, 2013-05, Vol.19 (5), p.352-353

2013

Volltextzugriff (PDF)

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

European journal of cancer (1990), 2020-03, Vol.127, p.150-157

2020

Volltextzugriff (PDF)

Prognostic factors in curative treatment of gallbladder cancer - Data of 950 cases of “The German- Registry”

Annals of oncology, 2016-10, Vol.27, p.vi210-vi210

2016

Volltextzugriff (PDF)

Multimodale Therapie des lokalisierten Magenkarzinoms

Der Onkologe, 2016-06, Vol.22 (6), p.392-399

2016

Volltextzugriff (PDF)

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors

BMC cancer, 2016-07, Vol.16 (1)

2016

Volltextzugriff (PDF)

1 – 25 von 136

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(128)

Publikationsform

Sprache

Englisch
(122)
Deutsch
(14)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Oncology
(23)
Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Humans
(18)
Male
(11)
Female
(10)
Treatment Outcome
(9)
Gastric Cancer
(8)
Tumors
(8)
Aged
(6)
Antineoplastic Agents
(6)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Middle Aged
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Medicine
(5)
Medicine & Public Health
(5)
Pharmacology. Drug Treatments
(5)
Prognosis
(5)
Clinical Trials
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)

“The German- Registry” of incidental gallbladder cancer and the GAIN - phase III trial: Transformation from a registry to treatment platform due to a trial in trial concept

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)

Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas

Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer

Quality of life (QoL) in patients with metastatic pancreatic cancer receiving first-line Nab-paclitaxel/gemcitabine chemotherapy: Results of the large QoL study AIO-QoliXane/PARAGON

Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)

Independent Radiological Evaluation of Objective Response Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306)

Vom „Stiefkind“ zum Paradebeispiel

Behandlungsalgorithmen für Adenokarzinome des Magens oder ösophagogastralen Übergangs

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

Prognostic factors in curative treatment of gallbladder cancer - Data of 950 cases of “The German- Registry”

Multimodale Therapie des lokalisierten Magenkarzinoms

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Aktive Filter

Suchergebnisse filtern